Five Prime Therapeutics Inc  

(Public, NASDAQ:FPRX)   Watch this stock  
Find more results for FPRX
-0.25 (-1.53%)
Mar 16 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 15.82 - 16.56
52 week 15.82 - 48.87
Open 16.37
Vol / Avg. 1.14M/601,939.00
Mkt cap 553.37M
P/E     -
Div/yield     -
EPS -4.41
Shares 34.86M
Beta 3.33
Inst. own 76%
Mar 12, 2018
Five Prime Therapeutics Inc at Cowen Health care Conference
Feb 27, 2018
Q4 2017 Five Prime Therapeutics Inc Earnings Call - Webcast
Feb 14, 2018
Five Prime Therapeutics Inc at Leerink Partners Global Healthcare Conference
Jan 9, 2018
Five Prime Therapeutics Inc at JPMorgan Healthcare Conference - Webcast
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin -15.80% -311.58%
Operating margin -226.45% -383.22%
EBITD margin - -376.86%
Return on average assets -2.39% -31.07%
Return on average equity -3.04% -37.49%
Employees 216 -
CDP Score - -


111 Oyster Point Blvd
United States - Map
+1-415-3655600 (Phone)
+1-415-3655601 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. Its preclinical programs include FPA150, FPA154 and FPT155.

Officers and directors

Lewis T. Williams M.D. Ph.D. Executive Chairman of the Board
Age: 67
Bio & Compensation  - Reuters
Aron Marc Knickerbocker MBA President, Chief Executive Officer, Chief Operating Officer, Director
Age: 47
Bio & Compensation  - Reuters
Marc L. Belsky Chief Financial Officer, Senior Vice President
Age: 61
Bio & Compensation  - Reuters
Kevin Baker Ph.D. Senior Vice President, Development Sciences
Age: 56
Bio & Compensation  - Reuters
Helen Louise Collins M.D. Senior Vice President and Chief Medical Officer
Age: 54
Bio & Compensation  - Reuters
Francis Willard Sarena J.D. Chief Strategy Officer and Secretary
Age: 46
Bio & Compensation  - Reuters
Mark D. McDade Lead Independent Director
Age: 61
Bio & Compensation  - Reuters
Garry Nicholson Director
Bio & Compensation  - Reuters
Franklin M. Berger Independent Director
Age: 67
Bio & Compensation  - Reuters
Fred E. Cohen Ph.D. M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters